EnduraKT https://endurakt.com Wed, 22 Nov 2023 06:26:10 +0000 en-US hourly 1 https://wordpress.org/?v=6.9.4 InfuSystem and Ventis Pharma’s Revolutionary Pain Management Solution https://endurakt.com/infusystem-and-ventis-pharmas-revolutionary-pain-management-solution/ https://endurakt.com/infusystem-and-ventis-pharmas-revolutionary-pain-management-solution/#respond Fri, 06 Oct 2023 16:52:58 +0000 https://lightpink-lapwing-412913.hostingersite.com/?p=1802

A Game-Changing Partnership: InfuSystem and Ventis Pharma’s Revolutionary Pain Management Solution

In an era marked by the ongoing opioid epidemic, it is with great enthusiasm that we introduce a groundbreaking partnership that promises to revolutionize pain management in hospitals across the nation. InfuSystem Holdings, Inc. and Ventis Pharma have joined forces to bring you an innovative solution that puts patient well-being at the forefront of healthcare.

A New Dawn in Pain Management

InfuSystem, a leading national healthcare service provider, and Ventis Pharma, a global pioneer in surgical and chronic pain management, have inked a national sales and marketing agreement. This alliance is set to reshape the way we approach pain management, particularly in post-operative and chronic pain scenarios.

Endura-KT™: A Non-Opioid Alternative

At the heart of this collaboration lies Ventis Pharma’s patented Endura-KT™, a groundbreaking local anesthetic compound that is set to change the landscape of pain relief. Comprising three non-opioid drugs – tetracaine, lidocaine, and epinephrine – Endura-KT™ provides an effective alternative to traditional opioid-based painkillers. It aligns perfectly with the current healthcare trend of multimodal pain management, aiming to reduce or eliminate opioid usage by combining various non-narcotic medications and techniques.

A Safer and More Effective Approach

Ventis Pharma’s products are renowned for their innovative, long-acting, and low-toxicity design. They are meticulously crafted to minimize surgical pain and address chronic pain conditions with utmost safety and efficiency. What sets these products apart is their cost-effectiveness, making high-quality pain relief accessible to patients nationwide.

A Shared Commitment to Combatting the Opioid Epidemic

The opioid epidemic is a grave healthcare crisis in North America, and both InfuSystem and Ventis Pharma are fully dedicated to playing their part in reducing the reliance on oral opioids. This partnership is not merely about business; it’s about reshaping the future of pain management for the better.

The Future of Healthcare

This collaboration not only expands InfuSystem’s offerings but also enhances the effectiveness of each sales call. It’s about providing healthcare professionals and patients with a safer, more patient-centric alternative to oral opioids, ultimately improving the quality of life for all.

Looking Ahead: A Shared Vision

Tim Patrick, CEO of Ventis Pharma, aptly points out that Endura-KT™ provides a superior option for anesthesiologists, surgeons, and CRNAs compared to existing non-opioid post-op local anesthetics. The focus is on delivering better medicine to more people while improving the patient’s healthcare experience.

About Ventis Pharma

Ventis Pharma is a biopharmaceutical company dedicated to developing and producing innovative pain management therapies, with a focus on post-operative surgical pain and chronic pain syndromes. Their products are safe, effective, and suitable for both adults and children, aligning perfectly with the mission to improve patient care.

About InfuSystem Holdings, Inc.

InfuSystem Holdings, Inc. is a leading national healthcare service provider, delivering outpatient care for durable medical equipment manufacturers and healthcare providers. Their two-platform model includes Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services), enabling them to provide a comprehensive and patient-centric solution.

A Shared Vision for a Pain-Free Future

In conclusion, the partnership between InfuSystem and Ventis Pharma is a testament to a shared vision: a future where patients can manage pain safely and effectively without the risks associated with opioids. Together, we’re leading the charge toward a brighter, pain-free tomorrow.

For more information, visit www.ventispharma.com and www.infusystem.com.

]]> https://endurakt.com/infusystem-and-ventis-pharmas-revolutionary-pain-management-solution/feed/ 0 ASRA and COA Conferences https://endurakt.com/asra-and-coa-conferences/ https://endurakt.com/asra-and-coa-conferences/#respond Fri, 06 Oct 2023 16:52:55 +0000 https://lightpink-lapwing-412913.hostingersite.com/?p=1801

Ventis Pharma's Success at ASRA and COA Conferences: A Glimpse into a Bright Future

We are thrilled to share some exciting updates from Ventis Pharma’s recent participation in two prestigious medical conferences, the ASRA and COA conferences. These events have been pivotal in showcasing our groundbreaking product, the Endura-KT™, to a captivated audience of medical professionals. In this blog post, we will recap the highlights from these conferences and the promising prospects that lie ahead for Ventis Pharma.

ASRA Conference, March 31st-April 2nd 2022:

Ventis Pharma had a remarkable presence at the ASRA (American Society of Regional Anesthesia and Pain Medicine) conference, held in Las Vegas. We extend our heartfelt gratitude to the dedicated team members who represented us at this event. The ASRA conference proved to be a tremendous success, with a resounding interest from anesthesiologists who are eager to incorporate Endura-Kit™ into their practice.

The buzz generated by Endura-KT™ at the ASRA conference was truly inspiring. Anesthesiologists recognized the significant impact our product can bring to the medical field, and the level of interest it garnered was unparalleled. Notably, several other medical companies expressed interest in representing our product, highlighting the widespread appeal of Endura-Kit™ among industry professionals.

COA Conference, April 7th-April 9th 2022:

Following our success at ASRA, Ventis Pharma continued its winning streak at the COA (California Orthopedic Association) conference in Indian Wells. Our team members showcased the unique formulation of Endura-KT™ and its potential to revolutionize patient outcomes in orthopedic surgery. The response from California orthopedic surgeons was nothing short of exceptional, as they expressed a deep intrigue in the product and its benefits.

Ventis Pharma is proud to acknowledge the excellent work of our team members at the COA conference. Their efforts resulted in significant interest and engagement with medical professionals who see the immense potential of Endura-KT™ in enhancing patient care in the orthopedic field.

Future Prospects:

The success at both ASRA and COA conferences has opened exciting doors for Ventis Pharma. We are delighted to announce that we are currently in the process of scheduling trials and usage studies for our product. The overwhelming interest and positive feedback received at these events have underscored the importance of advancing Endura-KT™ in the medical community.

As we move forward, Ventis Pharma remains committed to pushing the boundaries of medical innovation. We are dedicated to ensuring that Endura-KT™ reaches its full potential in improving patient outcomes and setting new standards in the healthcare industry.


Ventis Pharma’s remarkable achievements at the ASRA and COA conferences are a testament to our commitment to innovation and excellence. We extend our gratitude to our dedicated team members and express our excitement for the journey ahead as we continue to make a positive impact on the healthcare landscape.

]]> https://endurakt.com/asra-and-coa-conferences/feed/ 0